肝细胞癌中核转运系统的改变——治疗策略的新基础
肝细胞癌是全球高发恶性肿瘤,治疗选择有限且预后差。几乎所有信号转导通路都需穿越核膜并依赖核转运系统组分,包括核转运受体(如输入蛋白和输出蛋白)及核孔复合体。本文综述核转运系统改变及其作为肝细胞癌靶向治疗靶点的潜力,选择性核输出抑制剂已在多种恶性肿瘤中进入临床试验。
要点
- 肝细胞癌治疗选择有限、预后差,亟需新靶点。
- 几乎所有信号转导通路依赖核转运系统组分穿越核膜。
- 核转运系统成员是肝细胞癌有潜力的治疗干预靶点。
核心结论
- 核转运系统成员的改变在肝细胞癌中具有靶向治疗潜力,选择性核输出抑制剂已在多种恶性肿瘤中进入临床试验。
研究设计与样本
- 综述,总结肝细胞癌中核转运系统改变及其靶向治疗潜力的现有知识。
主要发现
- 几乎所有信号转导级联均需穿越核膜,依赖核转运系统组分,包括核转运受体(如输入蛋白和输出蛋白)及核孔复合体。
- 核转运系统成员代表有前景的治疗干预靶点。
- 选择性核输出抑制剂已在多种恶性肿瘤中进入临床试验。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hepatocellular carcinoma (HCC) is among the most prevalent human malignancies worldwide with rising incidence in industrialised countries, few therapeutic options and poor prognosis. To expand and improve therapeutic strategies, identification of drug targets involved in several liver cancer-related pathways is crucial. Virtually all signal transduction cascades cross the nuclear envelope and therefore require components of the nuclear transport system (NTS), including nuclear transport receptors (e.g. importins and exportins) and the nuclear pore complex. Accordingly, members of the NTS represent promising targets for therapeutic intervention. Selective inhibitors of nuclear export have already entered clinical trials for various malignancies. Herein, we review the current knowledge regarding alterations of the NTS and their potential for targeted therapy in HCC.
引用
- Beck M, Schirmacher P, Singer S, et al. Alterations of the nuclear transport system in hepatocellular carcinoma - New basis for therapeutic strategies. J Hepatol. 2017. PMID: 28673770. doi:10.1016/j.jhep.2017.06.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。